ELANCO ANIMAL HEALTH INC (5EA.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:5EA - US28414H1032 - Common Stock
5EA.DE Key Statistics, Chart & Performance
The current stock price of 5EA.DE is 20.295 EUR.
5EA.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 10.85 | 200.25B | ||
| SAN.PA | SANOFI | 10.79 | 199.18B | ||
| 1SAN.MI | SANOFI | 10.83 | 199.98B | ||
| MRK.DE | MERCK KGAA | 15.18 | 56.29B | ||
| UNC.DE | UCB SA | 39.3 | 49.07B | ||
| UCB.BR | UCB SA | 39.42 | 49.23B | ||
| BAYN.DE | BAYER AG-REG | 7.3 | 38.28B | ||
| 1BAYN.MI | BAYER AG-REG | 7.42 | 38.90B | ||
| IPN.PA | IPSEN | 12.34 | 10.62B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.95 | 10.28B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 107.93 | 9.99B | ||
| VIRP.PA | VIRBAC SA | 20.76 | 3.02B |
Related stock screener links
About 5EA.DE
Company Profile
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Company Info
ELANCO ANIMAL HEALTH INC
450 Elanco Circle
Indianapolis INDIANA US
Employees: 9000
Phone: 18773526261
ELANCO ANIMAL HEALTH INC / 5EA.DE FAQ
Can you describe the business of ELANCO ANIMAL HEALTH INC?
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
What is the current price of 5EA stock?
The current stock price of 5EA.DE is 20.295 EUR. The price increased by 2.49% in the last trading session.
Does ELANCO ANIMAL HEALTH INC pay dividends?
5EA.DE does not pay a dividend.
How is the ChartMill rating for ELANCO ANIMAL HEALTH INC?
5EA.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for 5EA stock?
ELANCO ANIMAL HEALTH INC (5EA.DE) currently has 9000 employees.
Can you provide the ownership details for 5EA stock?
You can find the ownership structure of ELANCO ANIMAL HEALTH INC (5EA.DE) on the Ownership tab.
5EA.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 5EA.DE.
5EA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 5EA.DE. 5EA.DE may be in some trouble as it scores bad on both profitability and health.
5EA.DE Financial Highlights
Over the last trailing twelve months 5EA.DE reported a non-GAAP Earnings per Share(EPS) of 0.82. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.78% | ||
| ROA | 0.27% | ||
| ROE | 0.53% | ||
| Debt/Equity | 0.59 |
5EA.DE Forecast & Estimates
22 analysts have analysed 5EA.DE and the average price target is 22.07 EUR. This implies a price increase of 8.76% is expected in the next year compared to the current price of 20.295.
For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 5.5% for 5EA.DE